Cargando…

The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization

BACKGROUND: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in majo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadoglou, Nikolaos P. E., Korakas, Emmanouil, Karkos, Christos, Maratou, Eirini, Kanonidis, Ioannis, Plotas, Panagiotis, Papanas, Nikolaos, Moutsatsou, Paraskevi, Ikonomidis, Ignatios, Lambadiari, Vaia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582224/
https://www.ncbi.nlm.nih.gov/pubmed/34758835
http://dx.doi.org/10.1186/s12933-021-01411-6
_version_ 1784596939683135488
author Kadoglou, Nikolaos P. E.
Korakas, Emmanouil
Karkos, Christos
Maratou, Eirini
Kanonidis, Ioannis
Plotas, Panagiotis
Papanas, Nikolaos
Moutsatsou, Paraskevi
Ikonomidis, Ignatios
Lambadiari, Vaia
author_facet Kadoglou, Nikolaos P. E.
Korakas, Emmanouil
Karkos, Christos
Maratou, Eirini
Kanonidis, Ioannis
Plotas, Panagiotis
Papanas, Nikolaos
Moutsatsou, Paraskevi
Ikonomidis, Ignatios
Lambadiari, Vaia
author_sort Kadoglou, Nikolaos P. E.
collection PubMed
description BACKGROUND: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in major adverse cardiovascular events (MACE). METHODS: We enrolled 168 consecutive patients with symptomatic, established PAD, requiring revascularization by endovascular means of any or both of their lower limbs. 88 age- and sex-matched subjects with less than 2 classical cardiovascular risk factors served as controls. Clinical parameters, glycemic and lipid profile, RBP4 and adiponectin levels were assayed. The occurrence of MACE was recorded during the 6-month follow-up and patients were assigned to MACE and non-MACE subgroups. RESULTS: The presence of symptomatic PAD was significantly correlated with age, diabetes, hsCRP, RBP4 and low adiponectin levels (p < 0.05). After adjustment for age, RBP4 (β = 0.498, p < 0.001), and adiponectin (β = –0.288, p < 0.001) levels remained as independent predictors of PAD presence in the whole study cohort. At baseline, MACE subgroup appeared with higher RBP-4 and hsCRP serum levels than non-MACE subgroup (p < 0.001), but no differences were detected for adiponectin (p = 0.758). Serum RBP4 levels remained independent predictor of MACE (β = 0.455, p < 0.001) after adjustment for traditional cardiovascular risk factors. CONCLUSIONS: High RBP4 and low adiponectin serum levels are independently associated with PAD presence. In addition, RBP4 is an independent predictor of MACE incidence in symptomatic PAD patients.
format Online
Article
Text
id pubmed-8582224
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85822242021-11-15 The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization Kadoglou, Nikolaos P. E. Korakas, Emmanouil Karkos, Christos Maratou, Eirini Kanonidis, Ioannis Plotas, Panagiotis Papanas, Nikolaos Moutsatsou, Paraskevi Ikonomidis, Ignatios Lambadiari, Vaia Cardiovasc Diabetol Original Investigation BACKGROUND: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in major adverse cardiovascular events (MACE). METHODS: We enrolled 168 consecutive patients with symptomatic, established PAD, requiring revascularization by endovascular means of any or both of their lower limbs. 88 age- and sex-matched subjects with less than 2 classical cardiovascular risk factors served as controls. Clinical parameters, glycemic and lipid profile, RBP4 and adiponectin levels were assayed. The occurrence of MACE was recorded during the 6-month follow-up and patients were assigned to MACE and non-MACE subgroups. RESULTS: The presence of symptomatic PAD was significantly correlated with age, diabetes, hsCRP, RBP4 and low adiponectin levels (p < 0.05). After adjustment for age, RBP4 (β = 0.498, p < 0.001), and adiponectin (β = –0.288, p < 0.001) levels remained as independent predictors of PAD presence in the whole study cohort. At baseline, MACE subgroup appeared with higher RBP-4 and hsCRP serum levels than non-MACE subgroup (p < 0.001), but no differences were detected for adiponectin (p = 0.758). Serum RBP4 levels remained independent predictor of MACE (β = 0.455, p < 0.001) after adjustment for traditional cardiovascular risk factors. CONCLUSIONS: High RBP4 and low adiponectin serum levels are independently associated with PAD presence. In addition, RBP4 is an independent predictor of MACE incidence in symptomatic PAD patients. BioMed Central 2021-11-10 /pmc/articles/PMC8582224/ /pubmed/34758835 http://dx.doi.org/10.1186/s12933-021-01411-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Kadoglou, Nikolaos P. E.
Korakas, Emmanouil
Karkos, Christos
Maratou, Eirini
Kanonidis, Ioannis
Plotas, Panagiotis
Papanas, Nikolaos
Moutsatsou, Paraskevi
Ikonomidis, Ignatios
Lambadiari, Vaia
The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title_full The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title_fullStr The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title_full_unstemmed The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title_short The prognostic role of RBP-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
title_sort prognostic role of rbp-4 and adiponectin in patients with peripheral arterial disease undergoing lower limb endovascular revascularization
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582224/
https://www.ncbi.nlm.nih.gov/pubmed/34758835
http://dx.doi.org/10.1186/s12933-021-01411-6
work_keys_str_mv AT kadoglounikolaospe theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT korakasemmanouil theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT karkoschristos theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT maratoueirini theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT kanonidisioannis theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT plotaspanagiotis theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT papanasnikolaos theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT moutsatsouparaskevi theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT ikonomidisignatios theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT lambadiarivaia theprognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT kadoglounikolaospe prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT korakasemmanouil prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT karkoschristos prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT maratoueirini prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT kanonidisioannis prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT plotaspanagiotis prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT papanasnikolaos prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT moutsatsouparaskevi prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT ikonomidisignatios prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization
AT lambadiarivaia prognosticroleofrbp4andadiponectininpatientswithperipheralarterialdiseaseundergoinglowerlimbendovascularrevascularization